Japan
· Delayed Price · Currency is JPY MedRx Statistics
Total Valuation
MedRx has a market cap or net worth of JPY 2.94 billion. The enterprise value is 1.39 billion.
| Market Cap | 2.94B |
| Enterprise Value | 1.39B |
Important Dates
The last earnings date was Friday, May 9, 2025.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MedRx has 47.50 million shares outstanding. The number of shares has increased by 24.13% in one year.
| Current Share Class | 47.50M |
| Shares Outstanding | 47.50M |
| Shares Change (YoY) | +24.13% |
| Shares Change (QoQ) | +0.15% |
| Owned by Insiders (%) | 4.46% |
| Owned by Institutions (%) | 6.08% |
| Float | 44.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 11.37 |
| PB Ratio | 1.70 |
| P/TBV Ratio | 1.70 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -1.26 |
| EV / Sales | 5.37 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.68
| Current Ratio | 16.68 |
| Quick Ratio | 16.05 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -61.79% and return on invested capital (ROIC) is -36.14%.
| Return on Equity (ROE) | -61.79% |
| Return on Assets (ROA) | -34.54% |
| Return on Invested Capital (ROIC) | -36.14% |
| Return on Capital Employed (ROCE) | -59.92% |
| Revenue Per Employee | 11.77M |
| Profits Per Employee | -50.32M |
| Employee Count | 22 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 0.08 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -52.67% in the last 52 weeks. The beta is 0.59, so MedRx's price volatility has been lower than the market average.
| Beta (5Y) | 0.59 |
| 52-Week Price Change | -52.67% |
| 50-Day Moving Average | 71.24 |
| 200-Day Moving Average | 86.88 |
| Relative Strength Index (RSI) | 41.56 |
| Average Volume (20 Days) | 1,054,440 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MedRx had revenue of JPY 259.00 million and -1.11 billion in losses. Loss per share was -24.21.
| Revenue | 259.00M |
| Gross Profit | 258.00M |
| Operating Income | -1.04B |
| Pretax Income | -1.10B |
| Net Income | -1.11B |
| EBITDA | -999.75M |
| EBIT | -1.04B |
| Loss Per Share | -24.21 |
Balance Sheet
The company has 1.55 billion in cash and n/a in debt, giving a net cash position of 1.55 billion or 32.70 per share.
| Cash & Cash Equivalents | 1.55B |
| Total Debt | n/a |
| Net Cash | 1.55B |
| Net Cash Per Share | 32.70 |
| Equity (Book Value) | 1.73B |
| Book Value Per Share | 36.38 |
| Working Capital | 1.55B |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 99.61% |
| Operating Margin | -400.00% |
| Pretax Margin | -423.55% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MedRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.13% |
| Shareholder Yield | -24.13% |
| Earnings Yield | -37.59% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MedRx has an Altman Z-Score of 27.21.
| Altman Z-Score | 27.21 |
| Piotroski F-Score | n/a |